Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Share News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Former Indivior CEO pleads guilty in U.S. in opioid addiction treatment probe

Tue, 30th Jun 2020 21:48

(Adds comment from defense lawyer and Indivior)

By Nate Raymond

June 30 (Reuters) - Shaun Thaxter, the former chief
executive of drugmaker Indivior Plc, pleaded guilty on
Tuesday to a criminal charge arising out of a U.S. Justice
Department investigation into the marketing of its opioid
addiction treatment Suboxone.

Thaxter pleaded guilty in federal court in Abingdon,
Virginia to a misdemeanor count of introducing misbranded drugs
into interstate commerce. The plea came a day after Indivior
said he was stepping down as CEO.

Prosecutors said Thaxter failed to prevent employees from
sharing misleading safety information about the drug with
Massachusetts' Medicaid program as it considered expanding
coverage for it.

Wick Sollers, his attorney, said Thaxter was "unaware of the
alleged misstatements when they were made." Thaxter faces up to
one year in prison when he is sentenced on Sept. 29 and has
agreed to pay $600,000 in fines and forfeitures.

The plea came after Indivior in April 2019 was indicted and
charged with engaging in an illegal scheme to boost
prescriptions of Suboxone in one of the few corporate
prosecutions related to the U.S. opioid addiction
epidemic.

Prosecutors alleged Indivior deceived doctors and healthcare
benefit programs into believing the film version of Suboxone,
which has an opioid component, was safer and less susceptible to
abuse than similar drugs.

The indictment said Indivior also used an internet and
telephone program touted as a resource for opioid addicts to
connect them to doctors it knew were prescribing Suboxone and
other opioids at high rates and in suspect circumstances.

Prosecutors said the scheme began before British consumer
goods company Reckitt Benckiser spun off Indivior.
Reckitt Benckiser last year agreed to pay $1.4 billion to
resolved related claims.

Slough, England-based Indivior denies wrongdoing and is
scheduled to face trial in September. Indivior on Tuesday said
it is working to "resolve outstanding investigations and
litigations as expeditiously as possible."
(Reporting by Nate Raymond in Boston
Editing by Chris Reese and Marguerita Choy)

More News
18 Mar 2020 13:42

Wednesday broker round-up

(Sharecast News) - Polypipe: Deutsche Bank upgrades to buy with a target price of 550p.

Read more
18 Mar 2020 12:06

LONDON MARKET MIDDAY: Stocks Soaked In Red; Pound Drops Below USD1.20

LONDON MARKET MIDDAY: Stocks Soaked In Red; Pound Drops Below USD1.20

Read more
18 Mar 2020 11:59

EU drugs agency says no evidence ibuprofen worsens COVID-19

March 18 (Reuters) - The European Union's healthcare regulator on Wednesday said there currently is no evidence which links anti-inflammatory medicines such as ibuprofen with the worsening of COVID-19.The European Medicines Agency (EMA) said https...

Read more
18 Mar 2020 09:30

UK BROKER RATINGS SUMMARY: Jefferies And Exane BNP Both Raise Reckitt

UK BROKER RATINGS SUMMARY: Jefferies And Exane BNP Both Raise Reckitt

Read more
18 Mar 2020 08:09

LONDON BRIEFING: Caterers Suffer From Virus Alongside Travel Industry

LONDON BRIEFING: Caterers Suffer From Virus Alongside Travel Industry

Read more
17 Mar 2020 13:00

Tuesday broker round-up

(Sharecast News) - Ti Fluid Systems: Citigroup downgrades to neutral with a target price of 140p.

Read more
17 Mar 2020 10:39

UK WINNERS & LOSERS SUMMARY: Dixons Carphone Rises On Turnaround Steps

UK WINNERS & LOSERS SUMMARY: Dixons Carphone Rises On Turnaround Steps

Read more
17 Mar 2020 09:23

UK BROKER RATINGS SUMMARY: Goldman Sachs Raises Pearson And Informa

UK BROKER RATINGS SUMMARY: Goldman Sachs Raises Pearson And Informa

Read more
16 Mar 2020 13:45

UPDATE 1-No evidence ibuprofen bad for COVID-19 patients -Nurofen-maker

(Adds details, background)March 16 (Reuters) - Nurofen producer Reckitt Benckiser sought to quash warnings against taking the drug on Monday, saying it was not aware of any evidence that the pills' active ingredient ibuprofen adversely impacted pa...

Read more
13 Mar 2020 22:47

UPDATE 1-FOCUS-Cleaning product makers race to labs to bolster coronavirus claims

(Adds graphic)By Siddharth Cavale and Richa NaiduMarch 13 (Reuters) - As global makers of household cleaners race to pitch their products as coronavirus killers, one major company, Reckitt Benckiser, may have a leg up on the competition.The maker ...

Read more
13 Mar 2020 13:00

FOCUS-Cleaning product makers race to labs to bolster coronavirus claims

By Siddharth Cavale and Richa NaiduMarch 13 (Reuters) - As global makers of household cleaners race to pitch their products as coronavirus killers, one major company, Reckitt Benckiser, may have a leg up on the competition.The maker of Lysol and D...

Read more
12 Mar 2020 17:41

DIRECTOR DEALINGS: Reckitt Executive Sehgal Buys GBP558,000 In Shares

DIRECTOR DEALINGS: Reckitt Executive Sehgal Buys GBP558,000 In Shares

Read more
11 Mar 2020 13:37

Wednesday broker round-up

(Sharecast News) - Clinigen Group: Liberum upgrades to buy with a target price of 780.0p.

Read more
9 Mar 2020 18:48

DIRECTOR DEALINGS SUMMARY: Reckitt Operations Chief Spends GBP480,000

DIRECTOR DEALINGS SUMMARY: Reckitt Operations Chief Spends GBP480,000

Read more
5 Mar 2020 09:23

UK BROKER RATINGS SUMMARY: Bernstein Upgrades BAT To Outperform

UK BROKER RATINGS SUMMARY: Bernstein Upgrades BAT To Outperform

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.